Editas Medicine, Inc. (EDIT): restructuring charge — Editas halts reni-cel, cuts 65% workforce, shifts to in vivo gene editing

Editas Medicine, Inc.

Discontinues ex vivo reni-cel program for sickle cell and beta thalassemia; ends partnering process.
Reduces workforce by ~180 positions (65%); costs of $55-70M for discontinuation, $14-18M for reduction.
Cash runway extended to Q2 2027; focuses on in vivo pipeline, with human proof-of-concept target in ~2 years.
CMO Baisong Mei steps down Dec 31; board members Emma Reeve and Meeta Chatterjee resign; Jessica Hopfield becomes Chair.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Editas Medicine, Inc. announced a restructuring with charges of approximately $14.0 million to $18.0 million (approximately 180 positions, or approximately 65%).

Type: restructuring
Charge: approximately $14.0 million to $18.0 million
Headcount: approximately 180 positions, or approximately 65%

Exact text from the filing

The Company additionally expects to incur costs of approximately $14.0 million to $18.0 million related to the Reduction, primarily consisting of severance payments and employee benefit costs.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Editas Medicine, Inc. announced a restructuring with charges of approximately $55.0 million to $70.0 million affecting reni-cel program.

Type: restructuring
Charge: approximately $55.0 million to $70.0 million
Affected area: reni-cel program

Exact text from the filing

The Company expects to incur costs of approximately $55.0 million to $70.0 million related to the Discontinuation, as it completes the wind-down of various activities related to clinical development of reni-cel, including contract termination costs, impairment charges and non-cash charges, and may also incur additional costs not currently contemplated due to events that may occur as a result of or that are associated with the Discontinuation.

View on SEC.gov

Browse all restructurings & charges →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001650664-24-000141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.